Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid

Journal of Hepatology

Volumn 64, Issue 5, 2016, Pages 1158-1166

  Ijssennagger, Noortje ^a   Janssen, Aafke W F ^b   Milona, Alexandra ^a   Ramos Pittol, José M ^a   Hollman, Danielle A A ^a   Mokry, Michal ^c   Betzel, Bark ^d   Berends, Frits J ^d   Janssen, Ignace M ^d   Van Mil, Saskia W C ^a   Kersten, Sander ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Farnesoid X receptor; Gene expression profiling; Human liver slices; Obeticholic acid

Indexed keywords

BILE SALT EXPORT PUMP; CARRIER PROTEINS AND BINDING PROTEINS; CELL NUCLEUS RECEPTOR; CHOLESTEROL 7ALPHA MONOOXYGENASE; DIHYDROOROTATE DEHYDROGENASE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE 6 PHOSPHATASE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 18 BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; MELANOMA ANTIGEN 3; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; OBETICHOLIC ACID; PHOSPHORYLASE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP; RAP1 PROTEIN; SOLUTE CARRIER FAMILY 51 ALPHA SUBUNIT; SOLUTE CARRIER FAMILY 51 BETA SUBUNIT; UNCLASSIFIED DRUG; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; DNA; FARNESOID X-ACTIVATED RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; CHOLANGITIS; DRUG TARGETING; FATTY LIVER; GENE EXPRESSION PROFILING; GENE INDUCTION; GENETIC REGULATION; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER SLICE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; MICROARRAY ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; TRANSCRIPTION INITIATION;

ANIMALS; CHENODEOXYCHOLIC ACID; DISEASE MODELS, ANIMAL; DNA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICROARRAY ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTIONAL ACTIVATION;

EID: 84958087641     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.01.016     Document Type: Article

References (52)

1. S. Bellentani, F. Scaglioni, M. Marino, and G. Bedogni Epidemiology of non-alcoholic fatty liver disease Dig Dis 28 2010 155 161
2. B.A. Neuschwander-Tetri, R. Loomba, A.J. Sanyal, J.E. Lavine, M.L. Van Natta, M.F. Abdelmalek, and et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 385 2015 956 965
3. Y.D. Wang, W.D. Chen, D.D. Moore, and W. Huang FXR: a metabolic regulator and cell protector Cell Res 18 2008 1087 1095
4. B. Goodwin, S.A. Jones, R.R. Price, M.A. Watson, D.D. McKee, L.B. Moore, and et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis Mol Cell 6 2000 517 526
5. M. Ananthanarayanan, N. Balasubramanian, M. Makishima, D.J. Mangelsdorf, and F.J. Suchy Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor J Biol Chem 276 2001 28857 28865
6. L. Huang, A. Zhao, J.L. Lew, T. Zhang, Y. Hrywna, J.R. Thompson, and et al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3 J Biol Chem 278 2003 51085 51090
7. P.C. Pircher, J.L. Kitto, M.L. Petrowski, R.K. Tangirala, E.D. Bischoff, I.G. Schulman, and et al. Farnesoid X receptor regulates bile acid-amino acid conjugation J Biol Chem 278 2003 27703 27711
8. X.X. Wang, T. Jiang, Y. Shen, L. Adorini, M. Pruzanski, F.J. Gonzalez, and et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria Am J Physiol Renal Physiol 297 2009 F1587 F1596
9. X.X. Wang, T. Jiang, Y. Shen, Y. Caldas, S. Miyazaki-Anzai, H. Santamaria, and et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model Diabetes 59 2010 2916 2927
10. Y.D. Wang, W.D. Chen, M. Wang, D. Yu, B.M. Forman, and W. Huang Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response Hepatology 48 2008 1632 1643
11. S. Mudaliar, R.R. Henry, A.J. Sanyal, L. Morrow, H.U. Marschall, M. Kipnes, and et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease Gastroenterology 145 2013 e571
12. C. Lerche-Langrand, and H.J. Toutain Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology Toxicology 153 2000 221 253
13. A.W. Janssen, B. Betzel, G. Stoopen, F.J. Berends, I.M. Janssen, A.A. Peijnenburg, and et al. The impact of PPARalpha activation on whole genome gene expression in human precision cut liver slices BMC Genomics 16 2015 760
14. E.M. Brunt, C.G. Janney, A.M. Di Bisceglie, B.A. Neuschwander-Tetri, and B.R. Bacon Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions Am J Gastroenterol 94 1999 2467 2474
15. K.P. Batts, and J. Ludwig Chronic hepatitis. An update on terminology and reporting Am J Surg Pathol 19 1995 1409 1417
16. C.J. Sinal, M. Tohkin, M. Miyata, J.M. Ward, G. Lambert, and F.J. Gonzalez Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis Cell 102 2000 731 744
17. M.T. Donato, A. Lahoz, J.V. Castell, and M.J. Gomez-Lechon Cell lines: a tool for in vitro drug metabolism studies Curr Drug Metab 9 2008 1 11
18. P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels Role of bile acids and bile acid receptors in metabolic regulation Physiol Rev 89 2009 147 191
19. F.Y. Lee, H. Lee, M.L. Hubbert, P.A. Edwards, and Y. Zhang FXR, a multipurpose nuclear receptor Trends Biochem Sci 31 2006 572 580
20. N.Y. Kalaany, and D.J. Mangelsdorf LXRS and FXR: the yin and yang of cholesterol and fat metabolism Annu Rev Physiol 68 2006 159 191
21. H.K. Chong, A.M. Infante, Y.K. Seo, T.I. Jeon, Y. Zhang, P.A. Edwards, and et al. Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1 Nucleic Acids Res 38 2010 6007 6017
22. A.M. Thomas, S.N. Hart, B. Kong, J. Fang, X.B. Zhong, and G.L. Guo Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine Hepatology 51 2010 1410 1419
23. M. Rakhshandehroo, G. Hooiveld, M. Muller, and S. Kersten Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human PLoS One 4 2009 e6796
24. S.F. Schmidt, M. Jorgensen, A. Sandelin, and S. Mandrup Cross-species ChIP-seq studies provide insights into regulatory strategies of PPARgamma in adipocytes Transcription 3 2012 19 24
25. R.E. Soccio, G. Tuteja, L.J. Everett, Z. Li, M.A. Lazar, and K.H. Kaestner Species-specific strategies underlying conserved functions of metabolic transcription factors Mol Endocrinol 25 2011 694 706
26. K. Fon Tacer, A.L. Bookout, X. Ding, H. Kurosu, G.B. John, L. Wang, and et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse Mol Endocrinol 24 2010 2050 2064
27. F.G. Schaap, N.A. van der Gaag, D.J. Gouma, and P.L. Jansen High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis Hepatology 49 2009 1228 1235
28. E. Wunsch, M. Milkiewicz, U. Wasik, J. Trottier, A. Kempinska-Podhorodecka, E. Elias, and et al. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease Sci Rep 5 2015 13462
29. T. Nishimura, Y. Utsunomiya, M. Hoshikawa, H. Ohuchi, and N. Itoh Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain Biochim Biophys Acta 1444 1999 148 151
30. D. Jung, J.P. York, L. Wang, C. Yang, A. Zhang, H.L. Francis, and et al. FXR-induced secretion of FGF15/19 inhibits CYP27 expression in cholangiocytes through p38 kinase pathway Pflugers Arch 466 2014 1011 1019
31. P. Sterpetti, L. Marucci, C. Candelaresi, D. Toksoz, G. Alpini, L. Ugili, and et al. Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by Rho GTPase signals Am J Physiol Gastrointest Liver Physiol 290 2006 G624 G632
32. L. Guillemot, S. Paschoud, L. Jond, A. Foglia, and S. Citi Paracingulin regulates the activity of Rac1 and RhoA GTPases by recruiting Tiam1 and GEF-H1 to epithelial junctions Mol Biol Cell 19 2008 4442 4453
33. X. Guo, J.G. Williams, T.T. Schug, and X. Li DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1 J Biol Chem 285 2010 13223 13232
34. J.L. Garcia-Rodriguez, L. Barbier-Torres, S. Fernandez-Alvarez, V. Gutierrez-de Juan, M.J. Monte, E. Halilbasic, and et al. SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling Hepatology 59 2014 1972 1983
35. J. Xia, S.W. Scherer, P.T. Cohen, M. Majer, T. Xi, R.A. Norman, and et al. A common variant in PPP1R3 associated with insulin resistance and type 2 diabetes Diabetes 47 1998 1519 1524
36. L. Hansen, T. Hansen, H. Vestergaard, C. Bjorbaek, S.M. Echwald, J.O. Clausen, and et al. A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin Hum Mol Genet 4 1995 1313 1320
37. A.S. Doney, B. Fischer, J.E. Cecil, P.T. Cohen, D.I. Boyle, G. Leese, and et al. Male preponderance in early diagnosed type 2 diabetes is associated with the ARE insertion/deletion polymorphism in the PPP1R3A locus BMC Genet 4 2003 11
38. H. Maegawa, K. Shi, H. Hidaka, N. Iwai, Y. Nishio, K. Egawa, and et al. The 3'-untranslated region polymorphism of the gene for skeletal muscle-specific glycogen-targeting subunit of protein phosphatase 1 in the type 2 diabetic Japanese population Diabetes 48 1999 1469 1472
39. G. Wang, R. Qian, Q. Li, T. Niu, C. Chen, and X. Xu The association between PPP1R3 gene polymorphisms and type 2 diabetes mellitus Chin Med J (Engl) 114 2001 1258 1262
40. E.K. Speliotes, L.M. Yerges-Armstrong, J. Wu, R. Hernaez, L.J. Kim, C.D. Palmer, and et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits PLoS Genet 7 2011 e1001324
41. P. Leon-Mimila, J. Vega-Badillo, R. Gutierrez-Vidal, H. Villamil-Ramirez, T. Villareal-Molina, E. Larrieta-Carrasco, and et al. A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity Exp Mol Pathol 98 2015 178 183
42. T.M. Teslovich, K. Musunuru, A.V. Smith, A.C. Edmondson, I.M. Stylianou, M. Koseki, and et al. Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 2010 707 713
43. G.M. Hirschfield, A. Mason, V. Luketic, K. Lindor, S.C. Gordon, M. Mayo, and et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid Gastroenterology 148 2015 e758
44. V. Iadevaia, A. Rinaldi, L. Falasca, L.P. Pucillo, T. Alonzi, G. Chimini, and et al. ATP-binding cassette transporter 1 and transglutaminase 2 act on the same genetic pathway in the apoptotic cell clearance Cell Death Differ 13 2006 1998 2001
45. V. Demchev, G. Malana, D. Vangala, J. Stoll, A. Desai, H.W. Kang, and et al. Targeted deletion of fibrinogen like protein 1 reveals a novel role in energy substrate utilization PLoS One 8 2013 e58084
46. J.P. Davies, C. Scott, K. Oishi, A. Liapis, and Y.A. Ioannou Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia J Biol Chem 280 2005 12710 12720
47. U. Desai, E.C. Lee, K. Chung, C. Gao, J. Gay, B. Key, and et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice Proc Natl Acad Sci U S A 104 2007 11766 11771
48. N. Zhang, Z. Fu, S. Linke, J. Chicher, J.J. Gorman, D. Visk, and et al. The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism Cell Metab 11 2010 364 378
49. E. Egecioglu, M. Bjursell, A. Ljungberg, S.L. Dickson, J.J. Kopchick, G. Bergstrom, and et al. Growth hormone receptor deficiency results in blunted ghrelin feeding response, obesity, and hypolipidemia in mice Am J Physiol Endocrinol Metab 290 2006 E317 E325
50. A.H. Hasty, H. Shimano, J. Osuga, I. Namatame, A. Takahashi, N. Yahagi, and et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor J Biol Chem 276 2001 37402 37408
51. M. Fuchs, A. Hafer, C. Munch, F. Kannenberg, S. Teichmann, J. Scheibner, and et al. Disruption of the sterol carrier protein 2 gene in mice impairs biliary lipid and hepatic cholesterol metabolism J Biol Chem 276 2001 48058 48065
52. M. Bjursell, A.K. Gerdin, M. Jonsson, V.V. Surve, L. Svensson, X.F. Huang, and et al. G protein-coupled receptor 12 deficiency results in dyslipidemia and obesity in mice Biochem Biophys Res Commun 348 2006 359 366